Research programme: anti-GPVI antibodies - advanceCOR/MorphoSys
Alternative Names: GPVI-Antibody FabLatest Information Update: 11 Sep 2024
Price :
$50 *
At a glance
- Originator MorphoSys
- Developer advanceCor
- Class Anti-ischaemics; Antiplatelets; Antithrombotics; Fab fragments; Monoclonal antibodies; Plasma expanders; Vascular disorder therapies
- Mechanism of Action Platelet membrane glycoprotein VI inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Coronary disorders; Stroke
- No development reported Myocardial infarction
Most Recent Events
- 10 Sep 2024 Preclinical development in stroke is ongoing Germany (advanceCor pipeline, September 2024)
- 10 Sep 2024 Preclinical trials in Coronary disorders in Germany (Parenteral) prior to September 2024 (advanceCor pipeline, September 2024)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Myocardial-infarction in Germany (Parenteral)